Yousefi H, Yuan J, Keshavarz-Fathi M, Murphy JF, Rezaei N. Immunotherapy of cancers comes of age. Expert Rev Clin Immunol. 2017;13(10):1001–15.

Article  CAS  PubMed  Google Scholar 

Brower V. Checkpoint blockade immunotherapy for cancer comes of age. J Natl Cancer Inst. 2015;107(3).

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell Lung cancer. N Engl J Med. 2015;372(21):2018–28.

Article  PubMed  Google Scholar 

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell Lung cancer. Science. 2015;348(6230):124–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Golstein P, Griffiths GM. An early history of T cell-mediated cytotoxicity. Nat Rev Immunol. 2018;18(8):527–35.

Article  CAS  PubMed  Google Scholar 

Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the Tumor microenvironment. Science. 2015;348(6230):74–80.

Article  CAS  PubMed  Google Scholar 

Wang D, Gu J. VASC: dimension reduction and visualization of single-cell RNA-seq data by Deep Variational Autoencoder. Genom Proteom Bioinf. 2018;16(5):320–31.

Article  Google Scholar 

Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat Protoc. 2020;15(4):1484–506.

Article  CAS  PubMed  Google Scholar 

Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 2014;32(4):381–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aibar S, Gonzalez-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14(11):1083–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogata D, Namikawa K, Takahashi A, Yamazaki N. A review of the AJCC Melanoma staging system in the TNM classification (eighth edition). Jpn J Clin Oncol. 2021;51(5):671–4.

Article  PubMed  Google Scholar 

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93.

Article  PubMed  Google Scholar 

De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. Radiotherapy toxicity. Nat Rev Dis Primers. 2019;5(1):13.

Article  PubMed  Google Scholar 

Salas-Benito D, Perez-Gracia JL, Ponz-Sarvise M, Rodriguez-Ruiz ME, Martinez-Forero I, Castanon E, et al. Paradigms on Immunotherapy combinations with Chemotherapy. Cancer Discov. 2021;11(6):1353–67.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12(7):408–24.

Article  CAS  PubMed  Google Scholar 

Kamrani A, Hosseinzadeh R, Shomali N, Heris JA, Shahabi P, Mohammadinasab R, et al. New immunotherapeutic approaches for cancer treatment. Pathol Res Pract. 2023;248:154632.

Article  CAS  PubMed  Google Scholar 

Li Y, Liu X, Zhang X, Pan W, Li N, Tang B. Immune cycle-based strategies for Cancer Immunotherapy. Adv Funct Mater. 2021;31(50).

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.

Article  CAS  PubMed  Google Scholar 

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic Melanoma. N Engl J Med. 2010;363(8):711–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261–8.

Article  CAS  PubMed  Google Scholar 

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic Bladder cancer. Nature. 2014;515(7528):558–62.

Article  CAS  PubMed  Google Scholar 

Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang Y, Zhao X, Fu J, Wang H. Progress and challenges in Precise Treatment of Tumors with PD-1/PD-L1 blockade. Front Immunol. 2020;11:339.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, et al. Treatment of relapsed or refractory classical Hodgkin Lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020;34(2):533–42.

Article  CAS  PubMed  Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Five-year survival and correlates among patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-small Cell Lung Cancer treated with Nivolumab. JAMA Oncol. 2019;5(10):1411–20.

Article  PubMed  PubMed Central  Google Scholar 

Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 2019;71(3):543–52.

Article  CAS  PubMed  Google Scholar 

Maruhashi T, Sugiura D, Okazaki IM, Shimizu K, Maeda TK, Ikubo J, et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 2022;55(5):912–24. e8.

Article  CAS  PubMed  Google Scholar 

Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8(2):e001014.

Article  PubMed  PubMed Central  Google Scholar 

Tang R, Rangachari M, Kuchroo VK. Tim-3: a co-receptor with diverse roles in T cell exhaustion and tolerance. Semin Immunol. 2019;42:101302.

Article  CAS  PubMed  Google Scholar 

Kang CW, Dutta A, Chang LY, Mahalingam J, Lin YC, Chiang JM, et al. Apoptosis of Tumor infiltrating effector TIM-3 + CD8 + T cells in colon Cancer. Sci Rep. 2015;5:15659.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, et al. Tim-3 expression on Tumor-infiltrating PD-1 + CD8 + T cells correlates with poor clinical outcome in renal cell carcinoma. Cancer Res. 2017;77(5):1075–82.

Article  CAS  PubMed  Google Scholar 

Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957.

Article  PubMed  PubMed Central  Google Scholar 

Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276(1):112–20.

Article  CAS  PubMed  Google Scholar 

Shum B, Larkin J, Turajlic S. Predictive biomarkers for response to immune checkpoint inhibition. Semin Cancer Biol. 2022;79:4–17.

Article  CAS  PubMed  Google Scholar 

Ribas A, Wolchok JD. C